| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$268,577 ) |
| | 2025 | 2021 | EPIVAX INC | 188 VALLEY ST | PROVIDENCE | RI | 02909-2468 | PROVIDENCE | USA | R01AI132205 | Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine | 000 | 5 | NIH | 2/5/2025 | -$268,577 |
|
| Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | EPIVAX INC | 188 VALLEY ST | PROVIDENCE | RI | 02909-2468 | PROVIDENCE | USA | R43IP001225 | PA21259, SBIR, Phase I, Improving T cell Responses in Vaccines: Prediction and Validation Using Existing Databases, Immunoinformatics and In Vitro Assays | 01 | 1 | CDC | 2/12/2024 | $0 |
| | 2024 | 2023 | EPIVAX INC | 188 VALLEY ST | PROVIDENCE | RI | 02909-2468 | PROVIDENCE | USA | R43IP001225 | PA21259, SBIR, Phase I, Improving T cell Responses in Vaccines: Prediction and Validation Using Existing Databases, Immunoinformatics and In Vitro Assays | 02 | 1 | CDC | 9/18/2024 | $0 |
| | 2024 | 2023 | EPIVAX INC | 188 VALLEY ST | PROVIDENCE | RI | 02909-2468 | PROVIDENCE | USA | R43AI174486 | Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities | 000 | 1 | NIH | 2/13/2024 | $0 |
| | 2024 | 2022 | EPIVAX INC | 188 VALLEY ST | PROVIDENCE | RI | 02909-2468 | PROVIDENCE | USA | U01FD007760 | ISPRI-HCP: CHO protein impurity immunogenicity risk prediction for improving biosimilar product development and assessing product interchangeability | 000 | 1 | FDA | 7/16/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $599,847 ) |
| | 2023 | 2023 | EPIVAX INC | 188 VALLEY ST | PROVIDENCE | RI | 02909-2468 | PROVIDENCE | USA | R43IP001225 | PA21259, SBIR, Phase I, Improving T cell Responses in Vaccines: Prediction and Validation Using Existing Databases, Immunoinformatics and In Vitro Assays | 00 | 1 | CDC | 8/23/2023 | $299,930 |
| | 2023 | 2023 | EPIVAX INC | 188 VALLEY ST | PROVIDENCE | RI | 02909-2468 | PROVIDENCE | USA | R43AI174486 | Validation and Improvement of ISPRI-HCP: An Innovative Platform for Immunogenicity Risk Assessment of Process-related Protein Impurities | 000 | 1 | NIH | 7/27/2023 | $299,917 |
| | 2023 | 2021 | EPIVAX INC | 188 VALLEY ST | PROVIDENCE | RI | 02909-2468 | PROVIDENCE | USA | R01AI132205 | Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine | 000 | 5 | NIH | 9/11/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,999,984 ) |
| | 2022 | 2022 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | U01FD007760 | ISPRI-HCP: CHO protein impurity immunogenicity risk prediction for improving biosimilar product development and assessing product interchangeability | 000 | 1 | FDA | 8/24/2022 | $1,999,984 |
|
| Issue Date FY: 2021 ( Subtotal = $1,123,469 ) |
| | 2021 | 2021 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R01AI132205 | Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine | 000 | 5 | NIH | 7/26/2021 | $1,123,469 |
| | 2021 | 2019 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R43TR002441 | GAA-ITEM: Personalizing the Prediction of Anti-therapeutic Antibody Response in Pompe Disease Patients | 000 | 2 | NIH | 1/30/2021 | $0 |
| | 2021 | 2017 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R43AI118189 | Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza | 000 | 2 | NIH | 1/13/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $1,136,044 ) |
| | 2020 | 2020 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R01AI132205 | Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine | 001 | 4 | NIH | 8/21/2020 | $1,136,044 |
| | 2020 | 2020 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R01AI132205 | Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine | 000 | 4 | NIH | 7/14/2020 | $1,136,044 |
| | 2020 | 2020 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R01AI132205 | Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine | 001 | 4 | NIH | 8/21/2020 | -$1,136,044 |
|
| Issue Date FY: 2019 ( Subtotal = $1,281,782 ) |
| | 2019 | 2019 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R01AI132205 | Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine | 000 | 3 | NIH | 7/16/2019 | $1,148,204 |
| | 2019 | 2019 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R43TR002441 | GAA-ITEM: Personalizing the Prediction of Anti-therapeutic Antibody Response in Pompe Disease Patients | 001 | 2 | NIH | 4/22/2019 | $133,578 |
| | 2019 | 2018 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R43TR002441 | GAA-ITEM: Personalizing the Prediction of Anti-therapeutic Antibody Response in Pompe Disease Patients | 000 | 1 | NIH | 4/3/2019 | $0 |
| | 2019 | 2017 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R43AI118189 | Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza | 000 | 2 | NIH | 6/6/2019 | $0 |
|
| Issue Date FY: 2018 ( Subtotal = $1,481,495 ) |
| | 2018 | 2018 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R43DK115365 | Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease | 000 | 2 | NIH | 8/27/2018 | $139,842 |
| | 2018 | 2018 | EPIVAX, INC. | 146 CLIFFORD ST STE 3 | PROVIDENCE | RI | 02903-4163 | PROVIDENCE | USA | R43TR002441 | GAA-ITEM: Personalizing the Prediction of Anti-therapeutic Antibody Response in Pompe Disease Patients | 000 | 1 | NIH | 5/9/2018 | $191,402 |
| | 2018 | 2018 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R01AI132205 | Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine | 000 | 2 | NIH | 7/18/2018 | $1,150,251 |
| | 2018 | 2013 | EPIVAX, INC. | 188 VALLEY ST STE 424 | PROVIDENCE | RI | 02909-2464 | PROVIDENCE | USA | R44DK081261 | EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of | 000 | 4 | NIH | 9/30/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,688,716 ) |
| | 2017 | 2017 | EPIVAX, INC. | 146 CLIFFORD ST STE 3 | PROVIDENCE | RI | 02903-4163 | PROVIDENCE | USA | R43AI118189 | Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza | 000 | 2 | NIH | 6/21/2017 | $290,546 |
| | 2017 | 2017 | EPIVAX, INC. | 146 CLIFFORD ST STE 3 | PROVIDENCE | RI | 02903-4163 | PROVIDENCE | USA | R43DK115365 | Novel Antigen-Specific Immunomodulatory Tregitope-based Therapy to Address Autoimmune Pathogenesis in Graves' Disease | 000 | 1 | NIH | 8/24/2017 | $177,020 |
| | 2017 | 2017 | EPIVAX, INC. | 146 CLIFFORD ST STE 3 | PROVIDENCE | RI | 02903-4163 | PROVIDENCE | USA | R01AI132205 | Structure-Guided Design of CD4 T cell Memory-Enhanced rHA H7N9 Influenza Vaccine | 000 | 1 | NIH | 8/14/2017 | $1,221,150 |
| | 2017 | 2013 | EPIVAX, INC. | 146 CLIFFORD ST STE 3 | PROVIDENCE | RI | 02903-4163 | PROVIDENCE | USA | R43AI102454 | Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease | 000 | 2 | NIH | 1/31/2017 | $0 |
| | 2017 | 2013 | EPIVAX, INC. | 146 CLIFFORD ST STE 3 | PROVIDENCE | RI | 02903-4163 | PROVIDENCE | USA | R44DK081261 | EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of | 000 | 4 | NIH | 7/7/2017 | $0 |
| | 2017 | 2013 | EPIVAX, INC. | 146 CLIFFORD ST STE 3 | PROVIDENCE | RI | 02903-4163 | PROVIDENCE | USA | R43HL114308 | Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A | 000 | 2 | NIH | 3/8/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $300,000 ) |
| | 2016 | 2016 | EPIVAX, INC | 146 CLIFFORD STREET | PROVIDENCE | RI | 02903-4163 | PROVIDENCE | USA | R43AI118189 | Development of a Non-adjuvanted VLP Vaccine against Stealth H7N9 Influenza | 000 | 1 | NIH | 6/27/2016 | $300,000 |
| | 2016 | 2013 | EPIVAX, INC | 146 CLIFFORD STREET | PROVIDENCE | RI | 02903 | PROVIDENCE | USA | R44DK081261 | EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of | 000 | 4 | NIH | 9/15/2016 | $0 |
|
| Issue Date FY: 2015 ( Subtotal = $0 ) |
| | 2015 | 2013 | EPIVAX, INC | 146 CLIFFORD STREET | PROVIDENCE | RI | 02903 | PROVIDENCE | USA | R44DK081261 | EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of | 000 | 4 | NIH | 3/4/2015 | $0 |
| | 2015 | 2013 | EPIVAX, INC | 146 CLIFFORD STREET | PROVIDENCE | RI | 02903 | PROVIDENCE | USA | R43AI102454 | Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease | 000 | 2 | NIH | 8/31/2015 | $0 |
| | 2015 | 2013 | EPIVAX, INC | 146 CLIFFORD STREET | PROVIDENCE | RI | 02903 | PROVIDENCE | USA | R43HL114308 | Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A | 000 | 2 | NIH | 7/21/2015 | $0 |
|
| Issue Date FY: 2013 ( Subtotal = $1,403,925 ) |
| | 2013 | 2013 | EPIVAX, INC | 146 CLIFFORD STREET | PROVIDENCE | RI | 02903-4163 | PROVIDENCE | USA | R43HL114308 | Combined Factor VIII Replacement and Tolerance Therapy for Hemophilia A | 000 | 2 | NIH | 7/1/2013 | $376,351 |
| | 2013 | 2013 | EPIVAX, INC | 146 CLIFFORD STREET | PROVIDENCE | RI | 02903-4163 | PROVIDENCE | USA | R44DK081261 | EpiVax Phase II SBIR: Preclinical studies of Tregitope Delivery and Mechanism of | 000 | 4 | NIH | 3/20/2013 | $727,574 |
| | 2013 | 2013 | EPIVAX, INC | 146 CLIFFORD STREET | PROVIDENCE | RI | 02903-4163 | PROVIDENCE | USA | R43AI102454 | Inducing Tolerance to Enzyme Replacement Therapy for Pompe Disease | 000 | 2 | NIH | 7/22/2013 | $300,000 |
|
| Issue Date FY: 2012 ( Subtotal = $1,678,781 ) (Continued on the next page) |
|
